EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Genxone's Enterprise Value is zł13.96 Mil.
Genxone's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was zł-4.22 Mil. Therefore, Genxone's EV-to-FCF for today is -3.31.
The historical rank and industry rank for Genxone's EV-to-FCF or its related term are showing as below:
WAR:GX1'
s EV-to-FCF Range Over the Past 10 Years
Min: -116.49 Med: -0.61 Max: 53.88
Current: -3.31
During the past 6 years, the highest EV-to-FCF of Genxone was 53.88. The lowest was -116.49. And the median was -0.61.
WAR:GX1's EV-to-FCF is ranked worse than 100% of 378
companies
in the Biotechnology industry
Industry Median: 8.345
vs WAR:GX1: -3.31
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-06-03), Genxone's stock price is zł6.18.
Genxone's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was zł-1.139. Therefore, Genxone's PE Ratio for today is At Loss.
Genxone EV-to-FCF Historical Data
The historical data trend for Genxone's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Genxone's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genxone's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genxone's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Genxone's EV-to-FCF falls into.
Genxone's current Enterprise Value is zł13.96 Mil.
Genxone's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-4.22 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genxone (WAR:GX1) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Genxone's share price for today is zł6.18.
Genxone's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-1.139.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Genxone EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Genxone's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Genxone SA is a biotechnology company that applies nanopore sequencing technology (third-generation of NGS) to many areas of science and business, including genetic diagnostics and the food industry. It specializes in developing new products and solutions based on the latest technologies of nucleic acid sequencing. The company's services include NANOPORE SEQUENCING that includes Whole Genome Sequencing, Bespoke Analysis, Metagenome Sequencing, Bioinformatic Analysis, 16S and/or ITS Gene Sequencing, and RNA Sequencing; and DIAGNOSTIC TESTS that includes Gastrointestinal Infections Panel, Respiratory Infections Panel, Urogenital Infection Panel, and Nervous System Infection Panel.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
WAR:GX1 has been successfully added to your 